Opinion
Video
Impact of ICER Reports on Hemophilia Treatment Decisions
Russell P. Gollard, MD, FACP, analyzes the role of ICER reports in optimizing patient care and health care costs.
Russell P. Gollard, MD, FACP: I think that in terms of our concern with doing not just what is best for the patient but as adherence to the philosophical construct known as population health, we want to do the most effective treatment for the least cost. If we have the availability of newer agents or modalities of care that can reduce the total cost of care during the lifetime of the patient, or of the horse, we’re very, very interested in that. I think the value of emicizumab is really great, given that this drug does not have many of the adverse effects of some of the other agents we use and, in fact, reduces the number of bleeds, particularly the number of major bleeds which we see in patients. The fact that we’re able to use an engineered monoclonal antibody to interfere with the lack of factor 8 and the proclivity toward developing major bleeds has a great economic impact on the cost of care. Also, in the end, has a very beneficial effect on the overall health of the patient.
Transcript is AI generated and reviewed by an AJMC editor.
